Skip to Content

MT 100 Approval Status

  • FDA approved: No
  • Brand name: MT 100
  • Generic name: metoclopramide hydrochloride and naproxen sodium
  • Company: Pozen Inc.
  • Treatment for: Migraine

MT 100 (metoclopramide hydrochloride and naproxen sodium) is an investigational antiemetic and nonsteroidal anti-inflammatory drug (NSAID) combination intended for use in the treatment of migraine.

In May 2004, Pozen Inc. announced receipt of a Not Approvable Letter from the U.S. Food and Drug Administration (FDA) advising the company that the New Drug Application (NDA) for MT 100 had not been approved due to the risk of tardive dyskinesia associated with metoclopramide.

The company went on to receive FDA approval for MT 400, marketed as Treximet (sumatriptan and naproxen sodium), for the acute treatment of migraine attacks in April 2008.

Development Status and FDA Approval Process for MT 100

Aug  5, 2005POZEN Provides Results of FDA Advisory Committee Meeting on MT 100 (Naproxen Sodium and Metoclopramide Hydrochloride)
Jun 29, 2005FDA Sets August 4, 2005 for Advisory Committee Meeting to Consider Tardive Dyskinesia Risk with MT 100
Dec 21, 2004POZEN's MT 100 To Be Reviewed by Advisory Committee in May 2005

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.